260 completed, 23 terminated, 19 unknown, 17 recruiting. 343 Phase 2, 40 Phase 3, 34 Phase 1.
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RCT for the Chinese Medicine in Treating Hypercholesterolemia Dachaihu Decoction combined Erzhiwan with variation, Placebo granules - Hypercholesterolemia | Phase 2 | Not yet recruiting | Chinese University of Hong Kong | 70 | 2027-01-01 | 2026-07-30 |
| Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a) YKYY032 group, YKYY032 Placebo group - Hyperlipoproteinemia (a) | Phase 2 | Not yet recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 192 | 2026-11-20 | 2026-11-03 |
| EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1 / Phase 2 | Not yet recruiting | Editas Medicine, Inc. | 56 | 2026-11-01 | 2026-10-26 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease DR10624 Injection, Placebo - Hypertriglyceridemia | Phase 2 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 315 | 2026-10-01 | 2026-09-30 |
| A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease VERVE-102, Placebo - Atherosclerosis, Cardiovascular Disease | Phase 2 | Recruiting | Verve Therapeutics, Inc. | 175 | 2026-09-24 | 2026-11-10 |
| A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia HRS-7249 Injection - Hyperlipidemia | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 400 | 2026-09-11 | 2026-10-09 |
| A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia SYH2070, Placebo - Mixed Hyperlipidemia | Phase 2 | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 240 | 2026-07-15 | 2026-07-22 |
| Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study Colesevelam, Placebo - PFAS, Environmental Exposures | Phase 2 | Not yet recruiting | University of Rhode Island | 50 | 2026-07-01 | 2026-05-18 |
| A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia Alirocumab - Hypercholesterolemia | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 438 | 2026-06-17 | 2026-10-15 |
| A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia QCZ484, Inclisiran, QCZ484 placebo - Hypercholesterolaemia | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-05-29 | 2026-07-30 |
| A Study to Assess the Safety, Tolerability and Efficacy of ION775 ION775 - Hypertriglyceridemia, Severe Hypertriglyceridemia | Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 72 | 2026-05-12 | 2026-11-02 |
| Vascular Intervention Strategies Trial for Alzheimer's Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative - Hypertension, Hypercholesterolemia | Phase 2 | Not yet recruiting | University of Southern California | 10 | 2026-05-01 | 2026-05-04 |
| A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors SHR-1918 Injection, SHR-1918 Injection Placebo - Hypercholesterolemia | Phase 2 / Phase 3 | Recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 126 | 2026-04-30 | 2026-06-16 |
| RBD5044 in Chinese Participants With Hypertriglyceridemia RBD5044, Placebo - Hypertriglyceridemia | Phase 2 | Active not recruiting | Ribotek Biopharmaceuticals (Shandong) Co., Ltd | 40 | 2026-02-28 | 2026-08-24 |
| A Dose-exploration Study of EDP167 in HoFH EDP167 - Homozygous Familial Hypercholesterolemia (HoFH) | Phase 2 | Recruiting | Eddingpharm (Zhuhai) Co., Ltd. | 20 | 2026-02-06 | 2026-05-20 |
| DNV001 Injection in Patients With Hypercholesterolemia DNV001 Injection, Placebo - Primary Hypercholesterolemia | Phase 2 | Not yet recruiting | Hangzhou Dinovate Biotech Co., Ltd | 120 | 2026-02-05 | 2026-02-06 |
| Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia ARO-DIMERPA, Placebo - Hyperlipidemia; Mixed | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 78 | 2025-12-22 | 2026-10-13 |
| A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia Solbinsiran, Placebo - Severe Hypertriglyceridemia | Phase 2 | Recruiting | Eli Lilly and Company | 60 | 2025-12-08 | 2026-11-04 |
| A Study of DII235 in Adults With Elevated Lipoprotein(a) DII235, Saline - Lipoprotein Disorder | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 234 | 2025-12-02 | 2026-08-07 |
| A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia HRS-1301, Placebo - Hyperlipidemia | Phase 2 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 189 | 2025-11-25 | 2025-12-12 |
Showing 20 of 343. Sign in to see all of them.
Hypercholesterolemia (145) · Hypertriglyceridemia (80) · Dyslipidemias (46) · Hyperlipoproteinemia Type II (34) · Cardiovascular Diseases (26) · Diabetes Mellitus (19) · Homozygous Familial Hypercholesterolemia (19) · Hypertension (19) · Atherosclerosis (17) · Lipid Metabolism Disorders (16) · Metabolic Syndrome (16) · Metabolic Diseases (14) · Obesity (14) · Hyperlipoproteinemias (11)
Nutritional and Metabolic Diseases (341) · Metabolic Diseases (329) · Lipid Metabolism Disorders (327) · Dyslipidemias (297) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (57) · Genetic Diseases, Inborn (53) · Lipid Metabolism, Inborn Errors (52) · Metabolism, Inborn Errors (51) · Hyperlipoproteinemias (50) · Vascular Diseases (43) · Glucose Metabolism Disorders (41) · Cardiovascular Diseases (33) · Pathological Conditions, Signs and Symptoms (33) · Endocrine System Diseases (28)
Atorvastatin (34) · Ezetimibe (17) · Fenofibrate (11) · Rosuvastatin Calcium (11) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (10) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (10) · evolocumab (10) · alirocumab (9) · gemcabene (7) · mipomersen (7) · ALN-PCS (5) · BMS201038 (5) · Fish Oils (5) · Omacor (5) · Pravastatin (5)
Esperion Therapeutics, Inc. (10) · Amgen (9) · Novartis Pharmaceuticals (9) · Regeneron Pharmaceuticals (8) · Kastle Therapeutics, LLC (7) · Merck Sharp & Dohme LLC (7) · University Health Network, Toronto (7) · University of Toronto (7) · AstraZeneca (6) · Eli Lilly and Company (6) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · NeuroBo Pharmaceuticals Inc. (6) · Aegerion Pharmaceuticals, Inc. (5) · Akcea Therapeutics (5) · Chonbuk National University Hospital (5)
United States (170) · Canada (86) · Netherlands (35) · China (34) · Australia (19) · Germany (18) · Japan (17) · Denmark (14) · Italy (13) · Hungary (12) · Czechia (11) · Norway (11) · Spain (11) · France (10) · Poland (10)
Jean-Claude Tardif, MD (4) · David JA Jenkins, MD, PhD, DSc (3) · Rebecca J Brown, M.D. (3) · Abhimanyu Garg, MD (2) · Arshed A Quyyumi, MD (2)
PMID 30183102, PMID 37994400, PMID 22301925, PMID 26872608, PMID 28324110, PMID 31194872, PMID 34677608, PMID 20707601, PMID 21518985, PMID 24014831, PMID 25060413, PMID 25091629, PMID 25660356, PMID 28181260, PMID 29037448, PMID 33990512, PMID 34223895, PMID 38018702, PMID 38415744, PMID 40587053, PMID 11914243, PMID 12221048, PMID 12805393, PMID 16996859, PMID 17030154, PMID 17215532, PMID 17298834, PMID 17325296, PMID 17384435, PMID 17392721, PMID 17434849, PMID 17556685, PMID 17563345, PMID 17971707, PMID 17987126, PMID 18018771, PMID 18468736, PMID 19364997, PMID 19500003, PMID 19506174, PMID 19592624, PMID 19727665, PMID 19810001, PMID 19843338, PMID 20008831, PMID 20220185, PMID 20378080, PMID 20428452, PMID 20435205, PMID 20527967
2016 (4), 2005 (2), 2015 (1), 2017 (1), 2019 (1), K23HL169929 (1), M01RR000096 (1), M01RR000334 (1), P01HL059407 (1), P01HL116263 (1), R01DK058785 (1), R01DK088114 (1), R01HL042554 (1), R01HL057354 (1), R01HL070742 (1)